United States · FDA National Drug Code directory

HEPLISAV-B

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
50090-4526_bc19aced-d2fa-4b4f-8824-e15a56fe422d
Product NDC
50090-4526
Form
INJECTION, SOLUTION
Composition / generic term
Hepatitis B Vaccine (Recombinant) Adjuvanted
Labeler
A-S Medication Solutions
Marketing category
BLA
Marketing start / end (source format)
20180101
Source listing expiry
20261231

Source-listed ingredients

  • HEPATITIS B VIRUS SUBTYPE ADW HBSAG SURFACE PROTEIN ANTIGEN — 20 ug/.5mL

These values do not establish equivalence or a dose recommendation.

Packages

  • 5 SYRINGE in 1 CARTON (50090-4526-0) / .5 mL in 1 SYRINGE (50090-4526-1) · 50090-4526-0

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →